Loading...
Market
Will Sanofi's tolebrutinib receive EMA approval for non-relapsing secondary progressive MS by December 31, 2024?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
European Medicines Agency (EMA) official announcements
Story
Sanofi's Tolebrutinib Delays Progressive MS Disability by 31%
Sep 20, 2024, 09:40 AM
Sanofi has announced that its experimental drug, tolebrutinib, has shown promising results in delaying the progression of disability in patients with non-relapsing secondary progressive multiple sclerosis. According to data from a phase 3 trial, tolebrutinib delayed the worsening of the disease by 31%. This development provides hope for patients who currently have no effective treatment options. Sanofi's data indicates a significant 31% delay in disability progression onset.
View original story
Similar markets
FDA only • 25%
EMA only • 25%
Both FDA and EMA • 25%
Neither • 25%
Significantly better • 25%
Moderately better • 25%
Similar • 25%
Worse • 25%
Below 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
Above 30% • 25%
Yes • 50%
No • 50%
